3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Stomach Neoplasms
12
Neoplasms
8
Breast Neoplasms
5
Triple Negative Breast Neoplasms
4
Neoplasm Metastasis
4
Uterine Cervical Neoplasms
3
Small Cell Lung Carcinoma
3
Ovarian Neoplasms
3
Osteosarcoma
3
Cholangiocarcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
Drug-Related Side Effects and Adverse Reactions
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Biliary Tract Neoplasms
2
Advanced Solid Tumor
2
Advanced Gastric Cancer
2
Thyroid Neoplasms
1
Solid Tumor, Adult
1
Sarcoma
1
Quality of Life
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Mouth Neoplasms
1
Metastatic Castration Resistant Prostate Cancer
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
Filgrastim
5
Ifosfamide
3
Docetaxel
3
Carboplatin
3
belinostat
2
Sunitinib
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Gemcitabine
2
Etoposide
2
Epirubicin
2
Doxorubicin
2
toripalimab
1
temsirolimus
1
tanespimycin
1
resiquimod
1
poly ICLC
1
perifosine
1
pegfilgrastim
1
pazopanib
1
liposomal doxorubicin
1
ivosidenib
1
etoposide phosphate
1
enasidenib
1
apatinib
1
angiotensin I (1-7)
1
alanosine
1
Vincristine
1
Topotecan
1
Thiotepa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Chondrosarcoma
×
apatinib
×
Clear all
NCT04260113
2021-01-05
AIAC
Peking University People's Hospital
Phase NA
Completed
40 enrolled